Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited ...

Their work is published in the journal npj Genomic Medicine. High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer and is often diagnosed at an advanced ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

Olaparib, a PARP inhibitor, shows promise as a maintenance therapy for patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD-positive but BRCA wild-type.